TY  - JOUR
A1  - Yakoub-Agha, Ibrahim
A1  - Chabannon, Christian
A1  - Bader, Peter
A1  - Basak, Grzegorz W.
A1  - Bönig, Halvard-Björn
A1  - Ciceri, Fabio
A1  - Corbacioglu, Selim
A1  - Duarte, Rafael F.
A1  - Einsele, Hermann
A1  - Hudecek, Michael
A1  - Kersten, Marie José
A1  - Köhl, Ulrike
A1  - Kuball, Jürgen
A1  - Mielke, Stephan
A1  - Mohty, Mohamad
A1  - Murray, John
A1  - Nagler, Arnon
A1  - Robinson, Stephen
A1  - Saccardi, Riccardo
A1  - Sanchez-Guijo, Fermin
A1  - Snowden, John A.
A1  - Srour, Micha
A1  - Styczynski, Jan
A1  - Urbano-Ispízua, Álvaro
A1  - Hayden, Patrick J.
A1  - Kröger, Nicolaus
T1  - Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
T2  - Haematologica
N2  - Chimeric antigen receptor (CAR) T cells are a novel class of anti-cancer therapy in which autologous or allogeneic T cells are engineered to express a CAR targeting a membrane antigen. In Europe, tisagenlecleucel (Kymriah™) is approved for the treatment of refractory/relapsed acute lymphoblastic leukemia in children and young adults as well as relapsed/refractory diffuse large B-cell lymphoma, while axicabtagene ciloleucel (Yescarta™) is approved for the treatment of relapsed/refractory high-grade B-cell lymphoma and primary mediastinal B-cell lymphoma. Both agents are genetically engineered autologous T cells targeting CD19. These practical recommendations, prepared under the auspices of the European Society of Blood and Marrow Transplantation, relate to patient care and supply chain management under the following headings: patient eligibility, screening laboratory tests and imaging and work-up prior to leukapheresis, how to perform leukapheresis, bridging therapy, lymphodepleting conditioning, product receipt and thawing, infusion of CAR T cells, short-term complications including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, antibiotic prophylaxis, medium-term complications including cytopenias and B-cell aplasia, nursing and psychological support for patients, long-term follow-up, post-authorization safety surveillance, and regulatory issues. These recommendations are not prescriptive and are intended as guidance in the use of this novel therapeutic class.
Y1  - 2019
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/53554
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-535541
SN  - 1592-8721
SN  - 0390-6078
N1  - Copyright© 2020 Ferrata Storti Foundation
Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher.
VL  - 105
IS  - 2
SP  - 297
EP  - 316
PB  - Ferrata Storti Foundation
CY  - Pavia
ER  -